CYP2A6 and ERCC1 Polymorphisms and Cancer Treatment
Author Information
Author(s): Park S R, Kong S-Y, Nam B-H, Choi I J, Kim C G, Lee J Y, Cho S J, Kim Y W, Ryu K W, Lee J H, Rhee J, Park Y-I, Kim N K
Primary Institution: National Cancer Center, Republic of Korea
Hypothesis
CYP2A6 polymorphisms affect the clinical outcomes of patients undergoing S-1-containing chemotherapy for metastatic gastric cancer.
Conclusion
Polymorphisms of CYP2A6 and ERCC1 19442C>A correlated with the efficacy of S-1/cisplatin.
Supporting Evidence
- Patients with fewer CYP2A6 variants had better response rates.
- CYP2A6 genotype was significantly associated with time to progression.
- Overall survival varied significantly with CYP2A6 genotype.
Takeaway
This study found that certain genetic variations can help predict how well patients with stomach cancer will respond to a specific chemotherapy treatment.
Methodology
The study analyzed genetic polymorphisms in 108 metastatic gastric cancer patients treated with S-1 and cisplatin.
Potential Biases
Potential bias due to the retrospective nature of the study and lack of randomization.
Limitations
The study was retrospective, lacked pharmacokinetic data, and did not analyze polymorphisms in other relevant genes.
Participant Demographics
Median age was 57 years, with 68.5% male and 31.5% female participants.
Statistical Information
P-Value
p=0.004
Confidence Interval
95% CI, 43.3–62.3
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website